InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.16
(
0.47%
)
US TECH 100
18,052.80
(
0.20%
)
Dow Jones
39,497.54
(
0.13%
)
Brent Oil
79.95
(
0.93%
)
Bitcoin
58,522.56
(
-0.34%
)
Post# of 252823
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120253
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 228495

Thursday, 04/30/2020 4:33:23 PM

Thursday, April 30, 2020 4:33:23 PM

Post# of 252823
GILD 1Q20 HCV sales=$729M, +16% QoQ, -8% YoY. The geographic breakdown was: US $398M; EU $148M; RoW $183M.

http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-first-quarter-2020-financial-results

GILD’s worldwide HCV patient starts in 1Q20 (CC slide #43) was flat vs 4Q19 at 45K (increasing from 28K to 29K in the US), implying an increase in average selling price per HCV patient.

--
CC slides:
http://investors.gilead.com/static-files/af4599eb-4fb8-4cf7-96a1-38caf477e9b4

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up